MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    The cause of death in Parkinson’s disease

    K. Kamada, K. Kino, T. Takata (Kagawa, Japan)

    Objective: To investigate the causes of death in patients with Parkinson's disease at 6 hospitals in Kagawa Prefecture, Japan. Background: Not much literature exists on…
  • 2023 International Congress

    Recruitment of Parkinson’s disease patients with mild-to-moderate anxiety into a randomized controlled trial: Experience of a large Canadian tertiary movement disorders clinic

    J. Lam, J. Zhu, D. Meng, P. Uzelman, S. Appel-Cresswell (Vancouver, Canada)

    Objective: To report our experience of recruiting Parkinson’s disease (PD) patients with mild-to-moderate anxiety into a randomized controlled trial. Background: Anxiety is a common non-motor…
  • 2023 International Congress

    Empowerment of People with Parkinson`s disease: development, testing and evaluation of a cross-sectoral, intervention-based self-management program

    T. Thomsen, S. Skovbølling, M. Møller, V. Grønlund, M. Brønden, B. Biering-Sørensen (Glostrup, Denmark)

    Objective: The overall purpose of this study is to develop, test and evaluate the results of a self-management program targeted PwP with the aim of…
  • 2023 International Congress

    Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicentre, parallel, randomised, double blind, phase 2b clinical trial

    C. Laurencin, A. Marques, D. Dilly Duchez, C. Giordana, S. Meoni, M. Anheim, P. Boulinguez, B. Ballanger, S. Thobois (Lyon, France)

    Objective: We aimed to assess whether clonidine, a specific α2-adrenergic receptor agonist, would improve impulse controls disorders (ICDs). Background: ICDs are frequently encountered in Parkinson’s…
  • 2023 International Congress

    Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422

    W. Singer, A. Takeda, L. Kjærsgaard, J. Wiedemann, A. Berger, A. Varrone, A. Bidani, D. Meulien (Rochester, USA)

    Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…
  • 2023 International Congress

    Introducing the molecular subtyping of Progressive Supranuclear Palsy: a proof of concept

    I. Martinez-Valbuena, S. Lee, E. Santamaria, J. Fernandez-Irigoyen, B. Couto, N. Reyes, H. Tanaka, S. Forrest, A. Kim, H. Qamar, J. Li, A. Karakani, K. Senkevich, E. Rogaeva, N. Visanji, A. Lang, G. Kovacs (Toronto, Canada)

    Objective: To enhance understanding of the molecular mechanisms underlying disease heterogeneity in Progressive supranuclear palsy (PSP) Background: PSP is a 4R-tauopathy characterised by subcortical pathology…
  • 2023 International Congress

    Disease progression in multiple system atrophy: the value of clinical cohorts with long follow-up

    T. Saulnier, M. Fabbri, A. Pavy-Le Traon, M. Le Goff, C. Helmer, P. Péran, WG. Meissner, O. Rascol, C. Proust-Lima, A. Foubert-Samier (Bordeaux, France)

    Objective: To describe MSA progression according to the latent disease continuum and assess the value of long-term follow-up. Background: Although essential for therapeutic development, describing…
  • 2023 International Congress

    DYT1 gene mutation: an atypical presentation with myoclonic dystonia

    G. Belluscio, F. Valentino, G. Cosentino, S. Gana, R. Zangaglia, C. Pacchetti (Pavia, Italy)

    Objective: In the present work, we describe the case of a 54 years old man who presented a young-age onset (7-8 years old) of unilateral…
  • 2023 International Congress

    miRNAs from blood serum as an early diagnostic biomarker for Parkinson’s disease: A study in an animal model

    MD. Ahmad, PSD. Dholaniya (Hyderabad, India)

    Objective: This work aims to elucidate miRNA-based biomarkers for the early stages of Parkinson`s Disease diagnosis in a chemically induced PD rat model. Background: The…
  • 2023 International Congress

    Comparision of objective Parkinson’s disease monitoring systems and the interpretations of results

    G. Kilincalp, F. Grahn, H. Sabir, D. von Below, A. Jeppsson, A. Sjöström, F. Bergquist (Gothenburg, Sweden)

    Objective: To examine the agreeement between two objective Parkinson’s disease (PD) monitoring systems (PKG and STAT-ON) and clinical information from a resident physician’s interview or…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley